Last update 27 Dec 2024
MSD Italia Srl

MSD Italia Srl

Subsidiary Company|
1960|
Italy
|
500-1,000
|
www.msd-italia.it

Overview

Tags

Neoplasms
Respiratory Diseases
Other Diseases
Small molecule drug
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms4
Nervous System Diseases3
Hemic and Lymphatic Diseases3
Immune System Diseases3
Endocrinology and Metabolic Disease3
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug3
Monoclonal antibody1
Top 5 TargetCount
DNA2
PD-1(Programmed cell death protein 1)1
DHFR x GART x TYMS1

Related

4
Drugs associated with MSD Italia Srl
Pembrolizumab
Target
PD-1
Mechanism
PD-1 inhibitors
Active Org.
MSD KK [+84]
Originator Org.
Merck & Co., Inc.Merck & Co., Inc.
Active Indication
Locally Advanced Cervical Carcinoma [+525]
Inactive Indication
Acute lymphoblastic leukemia recurrent [+71]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date04 Sep 2014
Pemetrexed Disodium Hydrate
Target
DHFR x GART x TYMS
Mechanism
DHFR inhibitors [+2]
Active Org.
Janssen Research & Development LLC [+28]
Originator Org.
Eli Lilly & Co.Eli Lilly & Co.
Active Indication
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma [+24]
Inactive Indication
Adenocarcinoma [+85]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date04 Feb 2004
Carboplatin
Target
DNA
Mechanism
DNA inhibitors
Active Org.
Bristol-Myers Squibb KK [+19]
Originator Org.
Corden Pharma GmbH
Active Indication
Breast Cancer [+70]
Inactive Indication
Adenocarcinoma [+87]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date03 Mar 1989
2
Clinical Trials associated with MSD Italia Srl
NCT06155279 / RecruitingPhase 2IIT
Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
NCT06467383 / Not yet recruitingNot Applicable
A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
100 Clinical Results associated with MSD Italia Srl
Login to view more data
0 Patents (Medical) associated with MSD Italia Srl
Login to view more data
100 Deals associated with MSD Italia Srl
Login to view more data
100 Translational Medicine associated with MSD Italia Srl
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2
4
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free